Department of Haematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA, Nedlands University of Western Australia, Crawley, Australia.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
Ann Oncol. 2016 May;27(5):778-87. doi: 10.1093/annonc/mdw029. Epub 2016 Jan 22.
The last 5 years have seen significant advances in our understanding of the molecular pathogenesis of B-cell lymphomas. This has led to the emergence of a large number of new therapeutic agents exploiting precise aspects of the tumor cell's signaling pathways, surface antigens or microenvironment. The purpose of this comprehensive review is to provide a detailed analysis of the breakthrough agents in the field, with a focus on recent clinical data. We describe agents targeting the B-cell receptor pathway, Bcl-2 inhibitors, emerging epigenetic therapies, new monoclonal antibodies and antibody drug conjugates, selective inhibitors of nuclear export, agents targeting the programmed cell death axis and chimeric antigen receptor T cells.
过去 5 年，我们对 B 细胞淋巴瘤的分子发病机制的理解取得了重大进展。这导致了大量利用肿瘤细胞信号通路、表面抗原或微环境精确方面的新型治疗药物的出现。本综述的目的是详细分析该领域的突破性药物，并重点介绍最新的临床数据。我们描述了靶向 B 细胞受体途径的药物、Bcl-2 抑制剂、新兴的表观遗传学治疗方法、新型单克隆抗体和抗体药物偶联物、核输出选择性抑制剂、靶向程序性细胞死亡轴的药物和嵌合抗原受体 T 细胞。
